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Summary
Background—Stents are an alternative treatment to carotid endarterectomy for symptomatic
carotid stenosis, but previous trials have not established equivalent safety and efficacy. We
compared the safety of carotid artery stenting with that of carotid endarterectomy.
Methods—The International Carotid Stenting Study (ICSS) is a multicentre, international,
randomised controlled trial with blinded adjudication of outcomes. Patients with recently
symptomatic carotid artery stenosis were randomly assigned in a 1:1 ratio to receive carotid artery
stenting or carotid endarterectomy. Randomisation was by telephone call or fax to a central
computerised service and was stratified by centre with minimisation for sex, age, contralateral
occlusion, and side of the randomised artery. Patients and investigators were not masked to
treatment assignment. Patients were followed up by independent clinicians not directly involved in
delivering the randomised treatment. The primary outcome measure of the trial is the 3-year rate
of fatal or disabling stroke in any territory, which has not been analysed yet. The main outcome
measure for the interim safety analysis was the 120-day rate of stroke, death, or procedural
myocardial infarction. Analysis was by intention to treat (ITT). This study is registered, number
ISRCTN25337470.
Findings—The trial enrolled 1713 patients (stenting group, n=855; endarterectomy group,
n=858). Two patients in the stenting group and one in the endarterectomy group withdrew
immediately after randomisation, and were not included in the ITT analysis. Between
randomisation and 120 days, there were 34 (Kaplan-Meier estimate 4·0%) events of disabling
stroke or death in the stenting group compared with 27 (3·2%) events in the endarterectomy group
(hazard ratio [HR] 1·28, 95% CI 0·77–2·11). The incidence of stroke, death, or procedural
myocardial infarction was 8·5% in the stenting group compared with 5·2% in the endarterectomy
group (72 vs 44 events; HR 1·69, 1·16–2·45, p=0·006). Risks of any stroke (65 vs 35 events; HR
1·92, 1·27–2·89) and all-cause death (19 vs seven events; HR 2·76, 1·16–6·56) were higher in the
stenting group than in the endarterectomy group. Three procedural myocardial infarctions were
recorded in the stenting group, all of which were fatal, compared with four, all non-fatal, in the
endarterectomy group. There was one event of cranial nerve palsy in the stenting group compared
with 45 in the endarterectomy group. There were also fewer haematomas of any severity in the
stenting group than in the endarterectomy group (31 vs 50 events; p=0·0197).
© 2010 Elsevier Ltd. All rights reserved.
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Interpretation—Completion of long-term follow-up is needed to establish the efficacy of carotid
artery stenting compared with endarterectomy. In the meantime, carotid endarterectomy should
remain the treatment of choice for patients suitable for surgery.
Funding—Medical Research Council, the Stroke Association, Sanofi-Synthélabo, European
Union.
Introduction
Carotid endarterectomy became the treatment of choice for patients with recently
symptomatic, severe carotid artery stenosis after the publication of results from large
randomised trials that compared endarterectomy with best medical treatment alone. The
potential benefit of endovascular treatment (angioplasty with or without stenting) as an
alternative to carotid endarterectomy was first highlighted by the Carotid and Vertebral
Artery Transluminal Angioplasty Study (CAVATAS). This trial showed that endovascular
treatment largely avoided the main complications of the endarterectomy incision (namely
cranial nerve injury and severe haematoma). However, the rate of stroke or death within 30
days after treatment was high in both groups. Since completion of CAVATAS, stenting has
largely replaced angioplasty, and stents and protection devices specifically designed for the
carotid artery have been introduced. Two large randomised trials comparing use of carotid
stenting with endarterectomy for symptomatic stenosis have subsequently published short-
term outcomes and longer term results. The Stent-Protected Angioplasty versus Carotid
Endarterectomy (SPACE) trial in symptomatic patients did not show non-inferiority of
stenting compared with endarterectomy within 30 days after treatment and was stopped
early for reasons of futility and cost. The Endarterectomy versus Stenting in Patients with
Symptomatic Severe Carotid Stenosis (EVA-3S) trial was stopped early because of a
significantly lower rate of periprocedural stroke or death in the endarterectomy group than in
the stenting group. We report the short-term results of the International Carotid Stenting
Study (ICSS), a randomised trial comparing stenting versus endarterectomy for recently
symptomatic carotid artery stenosis.
Methods
Study centres and participants
ICSS is an international, multicentre, open, randomised controlled trial designed to compare
the safety and long-term efficacy of carotid stenting and endarterectomy. The protocol was
published in 2004 and is publically available on the trial website. ICSS was approved by the
Northwest Multicentre Research Ethics Committee in the UK and participating centres had
to obtain site-specific approval from their local ethics committees. All patients provided
written informed consent.
Participating centres had a team of investigators consisting of at least one neurologist or
physician with an interest in stroke, a surgeon with experience in endarterectomy, and a
physician or surgeon with expertise in carotid angiography, angioplasty, and stenting. All
centres were required to hold regular multidisciplinary meetings between the investigators to
discuss the management of patients with carotid stenosis. Investigators submitted their
curriculum vitae and audit data that documented satisfactory training and results of carotid
treatment to the credential committee. Centres were then enrolled as either experienced or
supervised centres on the recommendation of the committee. To qualify as experienced, a
centre had to have a surgeon who had done at least 50 carotid operations (ten or more cases
per year) and a physician or surgeon who had done a minimum of 50 stenting procedures,
with at least ten cases in the carotid artery. Centres not fulfilling these criteria joined as
supervised centres and their trial procedures had to be proctored by an outside surgeon or
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interventionist, appointed by the trial steering committee, until the proctor was satisfied that
the centre was proficient in undertaking the procedure. Supervised centres were promoted to
experienced centres after randomisation and treatment of 20 cases within the trial if their
results were deemed acceptable by the proctor and the credential committee.
Patients were eligible for enrolment if they were older than 40 years of age and had
symptomatic atheromatous carotid artery stenosis measured as more than 50% by the North
American Symptomatic Carotid Endarterectomy Trial criteria (or non-invasive equivalent)
deemed to require treatment. Symptoms attributable to the randomised artery needed to have
occurred within 12 months before randomisation.
Non-invasive imaging of the carotid artery, including duplex ultrasound, was acceptable for
study entry. Catheter angiography before randomisation was not required. Exclusion criteria
included major stroke without useful recovery of function, previous carotid endarterectomy
or stenting in the randomised artery, contraindications for either treatment, and planned
coronary artery bypass grafting or other major surgery.
At randomisation, patients had to be deemed suitable for both surgery and stenting by the
investigators, who also had to be uncertain which of the two treatments was the best option
for the patient. Patients unsuitable for stenting because of tortuous anatomy proximal or
distal to the stenosis, visible thrombus, proximal common carotid artery stenosis, or internal
carotid artery pseudo-occlusion were excluded, as were patients unsuitable for
endarterectomy because of the distal site of the stenosis, a rigid neck, or risk factors for
surgical complications. No record was kept of patients screened who were ineligible or
treated outside the trial. It was recommended that patients randomised to stenting after non-
invasive investigation, in which subsequent angiography before stenting showed one or
more exclusion criteria, should have the procedure abandoned and be treated by surgery, if
appropriate, or medical care alone. A similar approach was taken in patients randomised to
surgery.
Randomisation and masking
Eligible patients were randomly assigned in a 1:1 ratio to receive carotid artery stenting or
carotid endarterectomy by use of a computerised service provided by Oxford Clinical Trials
Service Unit staff who were not involved in other parts of the trial. The allocated treatment
was communicated to investigators or one of their research team by telephone or fax after
they provided baseline data for the patient. Randomisation was stratified by centre with
minimisation for sex, age, contralateral occlusion, and side of the randomised artery.
Investigators were kept masked about the randomisation program to prevent them
anticipating the next assignment. Patients and individuals who delivered the interventions
were not masked to treatment assignment. Patients were followed up by independent
clinicians who were not masked to treatment assignment but who were not directly involved
in delivering the randomised treatment. Adjudication of outcomes was blinded. Apart from
the trial statistician and the data monitoring committee, all investigators, including the chief
investigator, remained masked to the results of the trial until after recruitment was
completed.
Procedures
Carotid stenting or endarterectomy was deemed initiated if the patient had been given
general or local anaesthetic in preparation for the intervention, even if the procedure was
subsequently abandoned before stent deployment or endarterectomy. Stents and other
devices used for carotid stenting were chosen at the discretion of the interventionist but had
to have a CE mark. The protocol recommended that a cerebral protection device should be
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used whenever the local investigator thought that one could be used safely, but this was not
mandatory. A combination of aspirin and clopidogrel to cover stenting procedures was
recommended. Use of heparin and atropine or similar agent during the procedure was
mandatory. Surgeons were free to use standard or eversion endarterectomy. The use of local
or general anaesthesia, shunts, and patches was left to the discretion of the surgeon.
Outcome events and trial safety
The protocol specified that patients should be seen before randomisation and then followed
up 30 days after treatment, 6 months after randomisation, and then once a year after
randomisation by a clinician who was not involved in the revascularisation procedure. At
every visit, levels of impairment were assessed with the modified Rankin scale. Outcome
events were reported in detail to the central office by the local neurologist or stroke
physician. Major outcome events were submitted to an independent external adjudicator,
who was masked to treatment allocation and who determined the cause, severity, and
duration of the event. If this assessment differed from the initial assessment, a second
external adjudicator reviewed the event and any differences were resolved by consensus.
The primary analysis specified in the protocol was the difference between groups in long-
term rate of fatal or disabling stroke in any territory. Long-term was defined as 3 years and
therefore data are not yet available for this analysis. Here, we report the first secondary
analysis specified in the protocol: the differences in mortality and morbidity between groups
within 30 days of carotid treatment. The main endpoint for this analysis was defined before
analysis as any stroke, death, or procedural myocardial infarction. Secondary endpoints of
particular interest were any stroke, any stroke or death, any stroke or procedural death,
disabling stroke or death, and all-cause death. Events relating to the various components of
the main endpoint, cranial nerve palsies, and haematomas requiring surgery, transfusion, or
extended hospital stay, were analysed.
Stroke was defined as a rapidly developing clinical syndrome of focal disturbance of
cerebral function lasting more than 24 h or leading to death with no apparent cause other
than that of vascular origin. Stroke was classified as fatal if death attributed to stroke
occurred within 30 days of onset of stroke. Stroke or cranial nerve palsy were classified as
disabling if there was an increase in the Rankin score to 3 or more, attributable to the event
at 30 days after onset. The remaining non-fatal strokes were classified as non-disabling.
Myocardial infarction was defined by the presence of two of the following three criteria:
specific cardiac enzymes more than twice the upper limit of normal; history of chest
discomfort for at least 30 min; or the development of specific abnormalities (eg, Q waves)
on a standard 12-lead electrocardiograph. Death or myocardial infarction was defined as
procedural if it occurred within 30 days of stenting or endarterectomy. Transient ischaemic
attack was defined as an acute disturbance of focal neurological function with symptoms
lasting less than 24 h attributed to cerebrovascular disease, but was not included as an
outcome event in the analyses reported here.
The rate of reported events at individual centres was monitored at the central office. The
independent data monitoring committee met on a regular basis to review the accumulating
data and to monitor trial safety.
Statistical analysis
A large difference in outcomes between the stenting and endarterectomy groups was not
expected and the sample size was calculated to provide a reasonable estimate of the
treatment effect. A sample size of 1500 patients from experienced centres was chosen on the
basis that this would allow a 95% CI to be measured with a width of ±3·3 percentage points
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for the difference in risk of disabling stroke or death between treatment groups, based on an
average of 12·5% of patients having the outcome. We also calculated that this sample size
would allow a 95% CI to be measured with a width ±3·0 percentage points for the secondary
short-term outcome of 30-day stroke, death, or procedural myocardial infarction, on the
basis of an average of 10% of patients having the outcome.
Because some patients did not receive their allocated treatment and the timing of treatment
after randomisation varied, we undertook two main analyses: an intention-to-treat (ITT)
analysis of all events occurring up to 120 days after randomisation and a per-protocol
analysis of the procedural risk within 30 days of allocated treatment. All main analyses
combined patients from experienced and supervised centres.
The ITT analysis included all randomised patients and compared those allocated to stenting
with those allocated to endarterectomy, irrespective of whether they received their allocated
treatment or not. All events between randomisation and 120 days were included in the ITT
analysis, irrespective of whether they occurred within 30 days of treatment or not. This
analysis therefore compared the initial policy of referral for stenting with referral for
endarterectomy in terms of outcome over 120 days. The period of 120 days was chosen
because most patients should have had their treatment within 3 months of randomisation and
their 30-day post-treatment follow-up appointment within 4 months after randomisation.
Patients with less than 120 days of follow-up and without an event were censored on the
date of last follow-up. Censoring was assumed to be non-informative—ie, a censored patient
was assumed to have the same risk of an outcome event as those who had complete 120-day
follow-up. Kaplan-Meier methods were used to estimate 120-day probabilities of an event
and subsequently the absolute risk difference between the two treatment groups and
corresponding 95% CIs. Cox proportional hazard methods were used to calculate the relative
difference between treatment groups (hazard ratio, HR) and 95% CIs with endarterectomy as
the reference group. Log-rank tests were used to compare the two survival curves.
The 30-day per-protocol analysis of the procedural risk included only patients in whom the
allocated treatment was initiated as their first ipsilateral revascularisation procedure. Patients
who received the alternative revascularisation procedure as their first treatment (cross-
overs), or who received no revascularisation treatment were excluded from this analysis. All
outcome events occurring within 30 days after initiation of the first allocated treatment were
included. We included every patient in whom the allocated treatment was initiated in the
per-protocol analysis, even if the date of treatment was more than 120 days after
randomisation, or if the treatment was aborted after initiation. This per-protocol analysis
therefore compared the 30-day procedural risks of the two treatments in those patients in
whom the allocated procedure was completed or initiated. Binomial regression methods
were used to estimate the 30-day absolute risk differences and relative risk ratios together
with 95% CIs. χ2 tests were used to test for differences between the two treatment groups.
Several predefined exploratory subgroup analyses were undertaken to investigate whether
the relative treatment effect for the 120-day ITT short-term composite outcome of stroke,
death, or procedural myocardial infarction differed across various patient groups. Interaction
tests were done with Cox proportional hazard models. All analyses were done with Stata
release 11, apart from the meta-analysis, which was done with ReviewManager version 5.0.
This study is registered, number ISRCTN25337470.
Page 5
Published as: Lancet. 2010 March 20; 375(9719): 985–997.
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data
interpretation, or the writing of the report. The corresponding author had full access to all
the data in the study and had final responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial profile. Between May, 2001, and October, 2008, 1713 patients from
50 academic centres in Europe, Australia, New Zealand, and Canada were enrolled and
randomised. Three patients (stenting group, two; endarterectomy group, one) withdrew
consent immediately after randomisation and were excluded from the ITT analysis. 751
(88%) of 853 patients assigned to carotid stenting and 760 (89%) of 857 patients assigned to
endarterectomy were randomised at centres classified as experienced. Table 1 shows
baseline characteristics of study participants.
Most patients had their allocated treatment initiated (stenting group, n=828; endarterectomy
group, n=821). Nine patients allocated to stenting crossed over to surgery without an attempt
at the procedure and a further 16 had no attempted ipsilateral endarterectomy or stenting
procedure (figure 1). 15 patients allocated to endarterectomy crossed over to stenting
without an attempt at endarterectomy and 21 had no attempted ipsilateral procedure.
Monitoring of adverse events led to concern about the stenting results of two investigators at
supervised centres. These investigators were stopped from treating further patients within
the trial and their centres were suspended from randomisation. All the patients allocated to
stenting (n=11, five with disabling stroke or death) or endarterectomy during the same time
period (n=9, one with fatal stroke) at these centres were included in the analyses. One of the
two centres subsequently restarted randomisation with a different investigator performing
stenting.
Figure 2 shows the delay from randomisation to first initiated ipsilateral treatment in the per-
protocol analysis. Median delay from randomisation to treatment was shorter in the stenting
group than in the endarterectomy group, as was the delay from most recent ipsilateral event
to treatment (table 2).
Of the 828 patients in whom stenting was initiated as allocated, 64 (8%) had their procedure
aborted before the insertion of a stent (38 procedures were aborted because of difficulty
gaining access to the stenosis, 15 were aborted because of the finding of an occluded artery,
one patient had a fatal stroke, one patient had fatal myocardial infarction before completion
of treatment, two had other medical complications, and further investigation in seven
patients showed the artery to be <50% stenosed). Of the 62 patients whose stenting
procedure was aborted after initiation and who did not have a fatal event, 37 went on to have
an ipsilateral endarterectomy, whereas 25 continued with best medical care only. Only two
of the 821 patients whose allocated endarterectomy was initiated had their procedure aborted
(one patient had an allergic reaction during general anaesthesia; the other became distressed
and the endarterectomy had to be abandoned). Both patients subsequently had ipsilateral
stenting.
The following stents were each used in 10% or more of the 764 patients in whom stents
were inserted: Carotid Wallstent (Boston Scientific), Precision (Cordis), and Protégé (EV3).
The following were each used in less than 10% of patients: Acculink (Guidant), Xact
(Abbott), Smart (Cordis), Cristallo Ideale (Invatec), Exponent (Medtronic), Next Stent
(Boston Scientific). Protection devices were known to have been used in 593 (72%) of 828
patients. The following protection devices were each used in 10% or more of the patients in
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whom stenting was attempted: FilterWire EZ (Boston Scientific), Angioguard (Cordis),
Spider FX (EV3), and Emboshield (Abbott). A range of other protection devices were each
used in less than 5% of patients. In 27 patients, it was not clear whether or not a protection
device was used.
In the ITT analysis, between randomisation and 120 days, there was no significant
difference in the rate of disabling stroke or death between groups (stenting group, 4·0% vs
endarterectomy group, 3·2%; table 3).
The risk of stroke, death, or procedural myocardial infarction 120 days after randomisation
was significantly higher in patients in the stenting group than in patients in the
endarterectomy group (8·5% vs 5·2%), representing an estimated 120-day absolute risk
difference of 3·3% (95% CI 0·9–5·7) with an HR in favour of surgery of 1·69 (1·16–2·45,
log-rank p=0·006; figure 3, table 3). Most outcome events in the stent and endarterectomy
groups occurred within 30 days of the first ipsilateral procedure (61 of 72 events vs 31 of 44
events). A few events occurred after randomisation but before the date of treatment (two
patients vs one patient), or in patients who had no attempted ipsilateral procedure (three
patients vs six patients), or more than 30 days after treatment but within 120 days of
randomisation (six patients vs six patients).
Compared with endarterectomy, allocation to stenting had a greater 120-day risk of the
outcome measures of any stroke, any stroke or death, any stroke or procedural death, and
all-cause death (table 3). Most strokes within 120 days of randomisation were ipsilateral to
the treated carotid artery and most were ischaemic (table 4). There were very few
haemorrhagic strokes with only two patients in whom the cause of the stroke was uncertain.
The observed treatment effect was largely driven by the higher number of non-disabling
strokes in the stenting group, most of which had symptoms lasting for more than 7 days.
There was an excess of fatal strokes in the stenting group compared with the surgery group,
but little difference in the number of patients with disabling stroke within 120 days of
randomisation.
The per-protocol analysis included 1649 patients (stenting group, n=828; endarterectomy
group, n=821). Results for 30-day procedural risk mirrored the results of the intention-to-
treat analysis. Risk of stroke, death, or procedural myocardial infarction was higher in the
stenting group than in the endarterectomy group (30-day risk 7·4% vs 4·0%; risk difference
[RD] 3·3%, 95% CI 1·1–5·6; risk ratio [RR] 1·83, 1·21–2·77, χ2 p=0·003; table 5). Risk of
any stroke or death up to 30 days after treatment remained significantly higher in patients in
whom stenting was initiated than in patients with surgery initiated, but there was no
significant difference in the risk of disabling stroke or death between treatment groups.
There were more fatal strokes in the stenting group than in the endarterectomy group (eight
vs three), but difference in the risk of death alone was no longer significant (table 5). 43
(74%) of 58 strokes in the stenting group and 12 (44%) of 27 in the endarterectomy group
occurred on the day of the procedure.
Few procedural myocardial infarctions were recorded (three in the stenting group, all of
which were fatal, compared with five in the endarterectomy group). Cranial nerve palsies
were almost completely avoided by stenting (table 4; RR 0·02, 95% CI 0·00–0·16,
p<0·0001). The one cranial nerve palsy recorded in the stenting group occurred as a
complication of an endarterectomy done within 30 days of stenting. This patient and one
additional patient in the endarterectomy group required percutaneous endoscopic
gastrostomy feeding as a result of the cranial nerve palsies, which were classified as
disabling. There were also fewer haematomas of any severity in the stenting group than in
the endarterectomy group (table 4; RR 0·59, 0·38–0·93, p=0·0197), and fewer severe
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haematomas requiring surgical intervention, blood transfusion, or extended hospital stay
(table 4; RR 0·28, 0·13–0·62, p=0·0007).
A post-hoc sensitivity analysis was undertaken to examine if the results of the per-protocol
analysis were affected by inclusion of patients in whom the allocated procedure was initiated
but not completed. Exclusion of the 64 patients allocated to stenting and two patients
allocated to endarterectomy in whom the procedures were aborted after initiation—ie,
including only patients in whom the allocated procedure was completed as planned—made
little difference to the results (30-day risk of stroke, death, or procedural myocardial
infarction 7·6% in the stenting group vs 4·0% in the endarterectomy group; RD 3·6%, 95%
CI 1·3–5·9; RR 1·88, 1·24–2·86, p=0·002).
We undertook exploratory analyses of the composite outcome of stroke, death, or procedural
myocardial infarction for predefined subgroups (figure 4). These analyses suggested that
carotid stenting might have a similar risk to endarterectomy in women, but that the
intervention was more hazardous than endarterectomy in men. The difference was mainly
caused by a higher risk of stroke, death, or procedural myocardial infarction in women
assigned to endarterectomy than in men (7·6% vs 4·2%). However, the difference between
the hazard ratios comparing the risk of stenting with endarterectomy in men and women
only reached borderline significance (interaction p=0·071). Stenting was more hazardous,
and endarterectomy less hazardous, in patients without treated hypertension at baseline than
in patients with treated hypertension (figure 4).
There was also a suggestion that patients allocated to the stenting group had a similar risk of
stroke, death, or procedural myocardial infarction to those allocated to endarterectomy after
multiple ipsilateral symptoms, but compared with patients with only one event before
randomisation, the difference in the hazard ratios only reached borderline significance
(interaction p=0·055). There was no evidence that the relative increase in the hazard of an
event in the stenting group compared with the endarterectomy group differed significantly
across any other subgroups.
Discussion
Short-term results from this randomised controlled trial show that carotid endarterectomy is
safer than carotid stenting for treatment of patients with symptomatic carotid artery stenosis.
Patients allocated to stenting had a 3·3% higher risk of stroke, death, or procedural
myocardial infarction within 120 days of randomisation in the ITT analysis. In the per-
protocol analysis, the rate of any stroke or death within 30 days of treatment in the stenting
group was more than twice the rate recorded in the endarterectomy group. The difference
between groups in the per-protocol analysis was mainly attributable to an excess of non-
disabling stroke in the stenting group compared with the endarterectomy group, but there
were also more fatal strokes and fatal myocardial infarctions in the stenting group. By
contrast, the numbers of disabling strokes in the two groups were identical and the rate of
disabling stroke or death was not significantly different between groups.
Most strokes within 30 days of treatment were ipsilateral to the treated artery and most were
ischaemic. Despite the recommended use of combined antiplatelet therapy with aspirin and
clopidogrel before stenting and for 1 month afterwards, plus use of heparin during the
procedure, there were only two haemorrhagic strokes within 30 days of stenting compared
with five after endarterectomy, suggesting that dual antiplatelet therapy in this setting is
safe. However, this antithrombotic regimen did not reduce ischaemic stroke sufficiently in
the stenting group.
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The balance of risk in favour of surgery caused by an excess of non-disabling stroke in the
stenting group might be seen as partly offset by the fact that endarterectomy was associated
with more cranial nerve injuries and more severe haematomas than was stenting. However,
the long-term outcome of non-disabling stroke might be worse than that of non-disabling
cranial nerve palsy. A recent systematic review has highlighted the increased risk of
dementia associated with recurrent stroke and the long-term consequences of the non-
disabling strokes in our study might only become evident with further follow-up, which will
include measures of disability and quality of life.
Patients who received a stent had a shorter wait from most recent stroke or transient
ischaemic attack to treatment than did those who received endarterectomy, but even so only
25% of patients in the stenting group were treated within 14 days of symptoms, compared
with 18% of those in the endarterectomy group. However, there was no difference in the
risks of stenting compared with endarterectomy whether or not patients were treated within
14 days of symptoms or later. Several strokes occurred before treatment was initiated (five
vs seven) and several patients developed asymptomatic carotid artery occlusion before
treatment (five vs nine), emphasising the importance of treating carotid stenosis as soon as
possible after symptoms.
The results of our study are consistent with those seen in previous randomised trials. A new
analysis of events occurring within 30 days of treatment in CAVATAS also showed an
excess of minor strokes in patients assigned to endovascular treatment compared with those
assigned to endarterectomy, with no difference in rates of disabling stroke or death.
CAVATAS used outdated techniques and few patients had stents inserted. The first
multicentre randomised trial of carotid stenting with modern devices designed for the carotid
artery, the Stenting and Angioplasty with Protection in Patients at High Risk for
Endarterectomy (SAPPHIRE) trial, mostly recruited patients with asymptomatic stenosis at
high risk for endarterectomy. Therefore, the trial's findings, which suggested that stenting
was not inferior to endarterectomy, cannot be directly compared with our results. The
EVA-3S and SPACE trials recruited only symptomatic patients and had similar protocols to
our trial. We have therefore combined the published 30-day safety data from EVA-3S,
SPACE, and ICSS in a meta-analysis (figure 5). The summary statistic strongly favours
carotid endarterectomy (odds ratio for stroke, death, or myocardial infarction within 30 days
after the procedure 1·73, 95% CI 1·29–2·32). One further large randomised trial, the Carotid
Revascularization Endarterectomy vs Stenting Trial (CREST), has completed recruitment,
but has not yet published any safety data.
Since CAVATAS was completed, there has been a reduction in risk of adverse outcomes
associated with endovascular treatment, but the risk associated with endarterectomy has
reduced to a greater extent. The risk of stroke, death, or procedural myocardial infarction in
the stenting group of our trial is similar to the risk associated with carotid endarterectomy
that was reported in the European Carotid Surgery Trial (ECST) in 1998. By contrast, the
risk of stroke, death, or procedural myocardial infarction after endarterectomy in our trial
and in EVA-3S was approximately half that reported in ECST. This reduction in risk
probably reflects improved anaesthetic and surgical techniques, and improved medical
treatment before surgery. The low rate of myocardial infarction in our trial is consistent with
improved medical treatment before surgery.
Our results are applicable to the current practice of carotid stenting at most vascular centres.
The participating centres were representative of academic centres with substantial
experience of treating carotid stenosis and needed to show a high standard of practice before
they could join the trial. Our results could be criticised in that the experience of the
interventionists in carotid stenting was less than that of the surgeons in carotid
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endarterectomy. However, the risk of outcome events associated with stenting was lower in
inexperienced, supervised centres than in more experienced centres (figure 4) and there was
no significant difference in the excess hazard of stenting compared with endarterectomy
between supervised and experienced centres or between centres recruiting more or less than
50 patients; therefore, inexperience cannot explain our results. The EVA-3S trial also
showed no differences in the outcomes favouring endarterectomy related to the experience
of the interventionists or the number of procedures done within the trial.
There are several possible explanations for the excess of non-disabling stroke seen in the
stenting group compared with the endarterectomy group. Investigators who undertook
follow-up assessments were not masked to treatment allocation, leading to the possibility of
ascertainment bias of minor events. A post-analysis audit has confirmed that all but 77
patients were seen for follow-up by a neurologist or stroke physician, or by research nurses
or practitioners supervised by a neurologist, not directly involved in the revascularisation
procedures. A sensitivity analysis excluding the 77 patients seen for follow-up by a surgeon
only, provided similar results to those of the full analysis (data not shown), making it
unlikely that biased reporting affected the results. We were concerned that some short-lived
events might be missed in surgical patients operated on under general anaesthesia and
returned to surgical wards, whereas these events might not be missed in endovascular
patients treated under local anaesthesia. However, this hypothesis is an unlikely explanation
of our results, since most of the excess non-disabling strokes associated with stents lasted for
more than 7 days. The conclusion that the excess in non-disabling stroke cannot be
explained by bias is supported by the results of a blinded MRI subanalysis of this trial. This
subanalysis showed a significantly higher proportion of patients with new ischaemic lesions
on MRI in the stenting group than in the endarterectomy group (50% vs 17%, adjusted odds
ratio 5·21, 95% CI 2·78–9·79, p<0·0001).
The most likely explanation for the excess risk of non-disabling stroke associated with
stenting is that it is related to instrumentation of the carotid stenosis, given that most strokes
occurred on the day of treatment. Selection of patients could be important in keeping the
risks of instrumentation to a minimum. Future analyses of our trial will investigate
anatomical and clinical risk factors for procedural stroke, as well as the effects of stent
design and protection devices.
Our exploratory analyses suggested that carotid stenting might have a similar risk to
endarterectomy in women, but that the intervention was more hazardous than
endarterectomy in men. However, the difference between the hazard ratios comparing
stenting with endarterectomy in women and men did not reach statistical significance. The
difference seemed to be largely explained by a higher risk of outcome events associated with
endarterectomy in women than in men. The increased risk associated with endarterectomy in
women is a consistent feature of most large studies and was also seen in the EVA-3S trial, in
the pooled analysis of the major carotid endarterectomy trials, and in a systematic review of
the published series. Stenting seemed to be more hazardous, and endarterectomy less
hazardous, in patients without treated hypertension at baseline than in patients with treated
hypertension, but the reasons remain unclear. However, a systematic review of predictors of
stroke and death caused by carotid endarterectomy showed a similar increase in risk of
stroke or death associated with hypertension (HR 1·82, 95% CI 1·37–2·41, p<0·0001) in
accordance with our findings.
Our results suggest that carotid endarterectomy should remain the treatment of choice for
symptomatic patients with severe carotid stenosis suitable for surgery. Most patients had no
complications from either procedure. Thus, some patients might still opt for stenting after
being presented with the available evidence, especially if they have a strong preference for
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avoiding surgery. Since outcomes in the stenting group were similar to those reported after
carotid endarterectomy in previous trials that compared surgery with best medical treatment
alone, stenting is also likely to be better than no revascularisation in patients unwilling or
unable to have surgery because of medical or anatomical contraindications.
The aim of treatment for carotid stenosis is long-term prevention of stroke. The EVA-3S and
SPACE studies showed little difference between carotid stenting and endarterectomy groups
in the rates of ipsilateral non-perioperative stroke occurring more than 30 days after
treatment, but the length of follow-up in these studies was restricted to a maximum of 4
years and 2 years, respectively. CAVATAS had a longer follow-up period and reported a
higher 8-year rate of non-perioperative stroke in patients who received endovascular
treatment (21·1%) than in patients who received surgery (15·4%; HR 1·66, 95% CI 0·99–
2·80). Most of the divergence occurred more than 2 years after randomisation, which might
be partly explained by a higher incidence of restenosis after endovascular treatment than
after endarterectomy. However, CAVATAS included only a small proportion of patients
treated by use of a stent, and the long-term rate of restenosis after stent insertion remains
uncertain. Follow-up is therefore continuing in ICSS and further data will become available
from the trial in due course.
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Figure 1.
Trial profile
Data for the number of patients screened for eligibility were not recorded.
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Figure 2.
Time between randomisation and treatment
Cumulative number of patients in whom allocated treatment was initiated per protocol
plotted as a proportion of the total number randomised in each group (vertical axis), against
the delay between the dates of randomisation and treatment (horizontal axis). Only allocated
per-protocol treatment dates were counted.
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Figure 3.
Kaplan-Meier estimates of cumulative incidence of various outcome measures
Data were analysed by intention to treat. The numbers above the end of the lines are the
incidence estimates at 120 days after randomisation. HR=hazard ratio.
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Figure 4.
Subgroup analysis to compare the rates of stroke, death, or procedural myocardial infarction
in different subgroups
Subgroups are defined according to baseline characteristics and analysed by intention to
treat up to 120 days after randomisation, apart from time from event to treatment, which is
analysed per protocol. p values are associated with treatment-covariate interaction tests.
*Data are number of events of first stroke, death, or procedural myocardial infarction within
120 days of randomisation/number of patients (Kaplan-Meier estimate at 120 days).
†Patients with missing information were excluded from the analysis. ‡Time from the most
recent ipsilateral event before randomisation to the date of treatment, analysed per protocol
for 30-day procedural events only (results are relative risk and 95% CI at 30 days after
treatment).
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Figure 5.
Meta-analysis comparing safety of carotid artery stenting with endarterectomy in the recent
carotid stenting trials
Odds ratio for any stroke, death, or procedural myocardial infarction within 30 days of
treatment in the three recent trials of carotid artery stenting versus endarterectomy including
only symptomatic patients. Analysis is based on published results of per-protocol data. The
large diamond represents the odds ratio and 95% CI of the combined data. The summary
estimate statistic was calculated by use of a Mantel-Haenszel fixed-effect model; the centre
of the diamond is the point estimate, and its width the 95% CI. EVA-3S=Endarterectomy
versus Stenting in Patients with Symptomatic Severe Carotid Stenosis. SPACE=Stent-
Protected Angioplasty versus Carotid Endarterectomy. ICSS=International Carotid Stenting
Study.
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Table 1
Baseline characteristics of patients
Stenting group (n=853) Endarterectomy group (n=857)
Age (years) 70 (9) 70 (9)
Sex (male) 601 (70%) 606 (71%)
Vascular risk factors
Treated hypertension 587 (69%) 595 (69%)
Systolic blood pressure (mm Hg) 147 (24) 146 (24)
Diastolic blood pressure (mm Hg) 79 (12) 78 (13)
Cardiac failure 23 (3%) 47 (5%)
Angina in past 6 months 83 (10%) 77 (9%)
Previous myocardial infarction 151 (18%) 156 (18%)
Previous CABG 109 (13%) 116 (14%)
Atrial fibrillation 57 (7%) 59 (7%)
Other cardiac embolic source 19 (2%) 16 (2%)
Type 2 diabetes mellitus 134 (16%) 147 (17%)
Type 1 diabetes mellitus 50 (6%) 40 (5%)
Peripheral artery disease 139 (16%) 136 (16%)
Current smoker 205 (24%) 198 (23%)
Ex-smoker 408 (48%) 424 (49%)
Treated hyperlipidaemia 522 (61%) 562 (66%)
Cholesterol (mmol/L) 4·8 (1·3) 4·9 (1·3)
Degree of symptomatic carotid stenosis*
50–69% 92 (11%) 76 (9%)
70–99% 761 (89%) 781 (91%)
Degree of contralateral stenosis*
<50% 565 (66%) 561 (65%)
50–69% 128 (15%) 142 (17%)
70–99% 105 (12%) 110 (13%)
Occluded 49 (6%) 37 (4%)
Unknown 6 (1%) 7 (1%)
Most recent ipsilateral event†
Amaurosis fugax 148 (17%) 142 (17%)
Transient ischaemic attack 273 (32%) 303 (35%)
Ischaemic hemispheric stroke 393 (46%) 376 (44%)
Retinal infarction 26 (3%) 23 (3%)
Unknown 13 (2%) 13 (2%)
Event <6 months before randomisation 826 (97%) 816 (95%)
Event 6–12 months before randomisation‡ 27 (3%) 36 (4%)
Multiple ipsilateral symptoms before randomisation 330 (39%) 317 (37%)
Ipsilateral stroke before most recent ipsilateral event 131 (15%) 106 (12%)
Modified Rankin score at randomisation
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Stenting group (n=853) Endarterectomy group (n=857)
0–2 756 (89%) 744 (87%)
3–5§ 81 (9%) 99 (12%)
Unknown 16 (2%) 14 (2%)
Data are number (%) or mean (SD). CABG=coronary artery bypass graft.
*
Degree of stenosis measured by North American Symptomatic Carotid Endarterectomy Trial method at randomisation centre.
†
If two events were reported on the same day, the more serious of the two was counted (stroke>retinal infarction>transient ischaemic
attack>amaurosis fugax).
‡
In three patients the event was more than 12 months before randomisation and in two the date was unknown.
§
Some Rankin scores of 3 or more were caused by non-stroke disability.
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Table 2
Time from randomisation and from most recent ipsilateral event to allocated treatment
Stenting group (n=828) Endarterectomy group (n=821) p value*
Time from randomisation to treatment (days) 9 (5–17) 11 (5–24) <0·0001
≤14 578 (70%) 469 (57%) ..
>14 250 (30%) 352 (43%) ..
Time from most recent event to treatment (days) 35 (15–82) 40 (18–87) 0·013
≤14 205 (25%) 151 (18%) ..
>14 623 (75%) 668 (81%) ..
Data are number (%) or median (IQR) in the per-protocol analysis. Three patients in the endarterectomy group were randomised more than 12
months after onset of symptoms. The date of the most recent event was unknown in two patients (endarterectomy group).
*
Mann-Whitney U test.
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Table 3
Outcome measures within 120 days of randomisation (intention-to-treat population)
Stenting group (n=853) Endarterectomy group (n=857) Hazard ratio
(95% CI)
Risk difference, %
(95% CI)
p value*
Stroke, death or
procedural myocardial
infarction
72 (8·5%) 44 (5·2%) 1·69 (1·16 to
2·45)
3·3% (0·9 to 5·7) 0·006
Any stroke 65 (7·7%) 35 (4·1%) 1·92 (1·27 to
2·89)
3·5% (1·3 to 5·8) 0·002
Any stroke or death 72 (8·5%) 40 (4·7%) 1·86 (1·26 to
2·74)
3·8% (1·4 to 6·1) 0·001
Any stroke or
procedural death
68 (8·0%) 36 (4·2%) 1·95 (1·30 to
2·92)
3·8% (1·5 to 6·0) 0·001
Disabling stroke or
death
34 (4·0%) 27 (3·2%) 1·28 (0·77 to
2·11)
0·8% (−0·9 to 2·6) 0·34
All-cause death 19 (2·3%) 7 (0·8%) 2·76 (1·16 to
6·56)
1·4% (0·3 to 2·6) 0·017
Data are number of first events (Kaplan-Meier estimate at 120 days). Risk differences are calculated from Kaplan-Meier estimates at 120 days.
*
Log-rank test.
Published as: Lancet. 2010 March 20; 375(9719): 985–997.
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
Page 25
Table 4
Number of outcome events between randomisation and 120 days in the intention-to-treat (ITT) analysis and
between initiation of treatment and 30 days after treatment in the per-protocol analysis
ITT analysis (events up to 120 days after randomisation) Per-protocol analysis (events between 0 days and 30 days
after treatment)
Stenting group (n=853) Endarterectomy group (n=857) Stenting group (n=828) Endarterectomy group (n=821)
Any stroke 65* 35 58* 27
Ipsilateral stroke 58 30 52 25
Ischaemic stroke 63 28 56 21
Haemorrhagic stroke 3 5 2 5
Uncertain cause 0 2 0 1
Non-disabling stroke 39 14 36 11
Lasting fewer
than 7 days
9† 5‡ 8† 5‡
Lasting more
than 7 days
31 9 29 6
Disabling stroke 17§ 20 14 14
Fatal stroke 9 2 8 3
Procedural myocardial infarction 3 4 3 5
Non-fatal myocardial infarction 0 4 0 5¶
Fatal myocardial infarction 3 0 3 0
Death unrelated to stroke or myocardial
infarction
7 5 1 1
Cranial nerve palsy 1‖ 45 1‖ 45
Disabling cranial nerve palsy 1‖ 1 1‖ 1
Haematoma 31 50 30 50
Severe haematoma** 9 28 8 28
Data are number of first events of each type. See text for definition of per protocol.
*
In two patients this was a retinal infarction. One patient had both an ischaemic and a haemorrhagic stroke.
†
One patient had a subsequent fatal myocardial infarction and one patient also had a non-disabling stroke that lasted for more than 7 days.
‡
One patient had a subsequent disabling stroke.
§
Two patients subsequently died of a cause unrelated to stroke or myocardial infarction.
¶
One patient had a non-fatal myocardial infarction within 30 days of the first procedure, which was undertaken more than 120 days after
randomisation. This myocardial infarction was therefore excluded from the ITT analysis (which stopped at 120 days) but was included in the per-
protocol 30-day analysis that included all first ipsilateral allocated procedures.
‖
The cranial nerve palsy in this patient in the stenting group, which was initiated but aborted, occurred after endarterectomy done within 30 days of
the stenting procedure.
**
Severe haematoma was defined as one that required surgical evacuation or blood transfusion, or resulted in extended hospital stay.
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Table 5
Outcome measures between initiation of treatment and 30 days after treatment (per-protocol analysis)
Stenting group (n=828) Endarterectomy group (n=821) Risk ratio
(95% CI)
Risk difference, %
(95% CI)
p value*
Stroke, death, or
myocardial infarction
61 (7·4%) 33 (4·0%) 1·83 (1·21 to
2·77)
3·3% (1·1 to 5·6) 0·003
Any stroke 58 (7·0%) 27 (3·3%) 2·13 (1·36 to
3·33)
3·7% (1·6 to 5·8) 0·001
Any stroke or death 61 (7·4%) 28 (3·4%) 2·16 (1·40 to
3·34)
4·0% (1·8 to 6·1) 0·0004
Disabling stroke or
death
26 (3·1%) 18 (2·2%) 1·43 (0·79 to
2·59)
0·9% (−0·6 to 2·5) 0·23
Procedural death 11† (1·3%) 4 (0·5%) 2·73 (0·87 to
8·53)
0·8% (−0·1 to 1·8) 0·072
Data are number of first events (%). See text for definition of per protocol.
*χ2 test.
†
One patient had a fatal stroke but died more than 30 days after the procedure. The event is therefore counted in the fatal stroke outcome but not in
the procedural death outcome.
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